Detalles de la búsqueda
1.
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
N Engl J Med
; 389(20): 1839-1850, 2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37870973
2.
Lysyl Oxidase 3 Is a Dual-Specificity Enzyme Involved in STAT3 Deacetylation and Deacetylimination Modulation.
Mol Cell
; 65(2): 296-309, 2017 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-28065600
3.
Schwann cell-derived exosomes promote lung cancer progression via miRNA-21-5p.
Glia
; 72(4): 692-707, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38192185
4.
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.
Lancet
; 402(10400): 451-463, 2023 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37423228
5.
Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
Oncologist
; 2024 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38529688
6.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Cancer Immunol Immunother
; 73(7): 124, 2024 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727837
7.
Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Respir Res
; 25(1): 59, 2024 Jan 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38273401
8.
Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
Int J Cancer
; 153(3): 635-643, 2023 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37078587
9.
Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma.
Int J Cancer
; 152(7): 1490-1500, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36451312
10.
Hypomethylation of DYRK4 in peripheral blood is associated with increased lung cancer risk.
Mol Carcinog
; 62(11): 1745-1754, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37530470
11.
Screening anlotinib responders via blood-based proteomics in non-small cell lung cancer.
FASEB J
; 36(8): e22465, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35867072
12.
ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
BMC Med
; 20(1): 170, 2022 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35509036
13.
mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.
J Transl Med
; 20(1): 247, 2022 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35642038
14.
Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma.
Ann Surg Oncol
; 29(9): 5666-5678, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35543906
15.
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
BMC Cancer
; 22(1): 294, 2022 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305596
16.
FYB methylation in peripheral blood as a potential marker for the early-stage lung cancer: a case-control study in Chinese population.
Biomarkers
; 27(1): 79-85, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882057
17.
DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation.
Acta Pharmacol Sin
; 43(1): 157-166, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33758355
18.
Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update.
Chin J Cancer Res
; 34(1): 28-39, 2022 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35355930
19.
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Br J Cancer
; 125(3): 366-371, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34006926
20.
Single-cell RNA sequencing reveals cellular and molecular immune profile in a Pembrolizumab-responsive PD-L1-negative lung cancer patient.
Cancer Immunol Immunother
; 70(8): 2261-2274, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33506299